Verve Therapeutics, Inc. (VERV)

Market Cap	516.85M
Revenue (ttm)	11.76M
Net Income (ttm)	-200.07M
Shares Out	78.55M
EPS (ttm)	-3.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	985,338
Open	6.87
Previous Close	6.88
Day's Range	6.53 - 6.92
52-Week Range	6.42 - 21.42
Beta	1.70
Analysts	Buy
Price Target	35.33 (+436.93%)
Earnings Date	May 13, 2024

About VERV

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 17, 2021
• Employees: 255
• Stock Exchange: NASDAQ
• Ticker Symbol: VERV

Financial Performance

In 2023, VERV's revenue was $11.76 million, an increase of 505.77% compared to the previous year's $1.94 million. Losses were -$200.07 million, 27.1% more than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for VERV stock is "Buy." The 12-month stock price forecast is $35.33, which is an increase of 436.93% from the latest price.

Price Target

$35.33

(436.93% upside)

Analyst Consensus: Buy